A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 [HER2]-Positive Unresectable Locally Advanced [LA] or Metastatic Breast Cancer [mBC] [SAMANTHA]
| The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02913456 |
Recruitment Status : Active, not recruiting First Posted : September 23, 2016 Last Update Posted : January 5, 2022 |
Sponsor:
Hoffmann-La Roche
Information provided by [Responsible Party]:
Hoffmann-La Roche